Syndax Pharmaceuticals Inc (SNDX) Form 8-K — Jun 4, 2026
Syndax Pharmaceuticals announced a private placement of $250 million in 2.25% Convertible Senior Notes due 2031, with closing expected on June 10, 2026. The notes carry an initial conversion price of approximately $24.76 per share, representing a 35% premium to the company's last reported sale price on June 3, 2026. The company estimates net proceeds of approximately $243 million after deducting placement agent fees and expenses. Syndax intends to use the capital for general corporate purposes, including working capital, research and development, commercialization activities, and business development.
Key figures
- Debt Amount
- 250000000
- Interest Rate
- 2.25
- Maturity Date
- 2031-06-15
- Gross Proceeds
- 250000000
- Offering Price
- 24.76
- Net Proceeds
- 243000000
- Conversion Rate
- 40.3894
- Premium Percent
- 35
- Max Shares Issuable
- 13631400
Price after filing
Close on the filing date to close N calendar days later (from $18.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.